Patients aren’t asking “about patents.” They’re asking: “Will I be able to keep taking my medicine?”
If you’ve spent any time reading patient forums, search queries, or comment sections, you’ll notice a pattern: people rarely talk about “drug switching…

Evergreen the brand. Beat the generic.
That’s the quiet chess match playing out across pharma—where “innovation” isn’t always a new molecule, but a new way to extend exclusivity. And in this game, most teams are still reacting after the fact: after a p…

GPT, Rosalind, and the Generic Drug Question: What OpenAI’s Life Sciences Model Really Changes
The biotech world loves a good promise: faster discovery, cheaper development, and a future where “AI will shorten timelines.” But when the conversation turn…

Patent cliffs don’t just “happen.” They’re engineered—by timing, leverage, and payer behavior.
For pharma leaders, the phrase “beat the patent cliff” can sound like a slogan. But in practice, it’s a campaign discipline: anticipating when exclusivity …

OpenAI’s GPT + Rosalind Just Hit “Patent Gravity” — and Drug Discovery Is Feeling It
For years, the drug patent cliff has been the industry’s quiet metronome: once key exclusivities expire, revenue streams don’t just decline—they drop. Generics arrive,…

Predict the Attack: How to Forecast Paragraph IV Filings and Neutralize “Skinny Label” Threats
In pharma, the most expensive surprises rarely arrive with a press release. They arrive quietly—filed on a calendar you didn’t know you were watching.
Paragr…

Your drug’s “patent life” isn’t one number—it’s a moving target across the GCC. Here’s how to know what you’re really protecting.
If you’re a pharma leader, counsel, or BD executive, you’ve probably heard the same comforting phrase: “Our patent runs fo…

Unlocking the Hidden Timeline: How Long Do Drug Patents Last in the GCC?
Imagine investing millions into developing a groundbreaking medication, only to find out that your exclusive rights could expire sooner than expected, or worse, that your competit…

Your competitor isn’t “improving” the drug. They’re extending its life. Here are 4 signals to watch.
In pharma, time is the real battleground.
A competitor doesn’t always need to invent a new molecule to win the next chapter. Often, they simply keep th…

Biopharma bizdev teams don’t lose deals because they lack ambition. They lose them because they’re late to the timeline that actually matters.
In licensing, partnering, and commercial strategy, timing is everything. But “timing” isn’t just about when y…